Md. firm’s treatment earns FDA clearance for Covid patients with drug-resistant infections By: Washington Business Journal via Business Journals November 18, 2020 at 11:42 AM EST The Maryland biotech's virus-based therapy targets superbugs. Read More >> Related Stocks: Harbor Disruptive Innovation ETF